Protein kinase R

Mechanism of action

Protein kinase-R is activated by double-stranded RNA (dsRNA), introduced to the cells by a viral infection. In situations of viral infection, the dsRNA created by viral replication and gene expression binds to the N-terminal domain, activating the protein. PKR activation via dsRNA is length dependent, requiring the dsRNA to be 30 bp in length to bind to PKR molecules. However, excess dsRNA can diminish activation of PKR. Binding to dsRNA is believed to activate PKR by inducing dimerization of the kinase domains and subsequent auto-phosphorylation reactions. It is not yet established whether PKR activates in cis, with a protomer's activation loop reaching into its own catalytic site, or in trans, with the activation loop being phosphorylated in a face to face geometry by a conjugate protomer. PKR can also be activated by the protein PACT via phosphorylation of S287 on its M3 domain. The promoter region of PKR has interferon-stimulated response elements to which Type I interferons (IFN) bind to induce the transcription of PKR genes. Some research suggests that PKR can be stimulated by heat shock proteins, heparin, growth factors, bacterial infection, pro-inflammatory cytokines, reactive oxygen species, DNA damage, mechanical stress, and excess nutrient intake.

Once active, PKR is able to phosphorylate the eukaryotic translation initiation factor eIF2α. This inhibits further cellular mRNA translation, thereby preventing viral protein synthesis. Overall, this leads to apoptosis of virally infected cells to prevent further viral spread. PKR can also induce apoptosis in bacterial infection by responding to LPS and proinflammatory cytokines. Apoptosis can also occur via PKR activation of the FADD and caspase signaling pathway.

PKR also has pro-inflammatory functions, as it can mediate the activation of the transcription factor NF-kB, by phosphorylating its inhibitory subunit, IkB. This leads to the expression of adhesion molecules and transcription factors that activate them, which induce inflammation responses such as the secretion of pro-inflammatory cytokines. PKR also activates several mitogen-activated protein kinases (MAPK) to lead to inflammation.

To balance the effects of apoptosis and inflammation, PKR has regulatory functions. Active PKR is also able to activate tumor suppressor PP2A which regulates the cell cycle and the metabolism. There is also evidence that PKR is autophagic as a regulatory mechanism.

PKR stress pathway

PKR is in the center of cellular response to different stress signals such as pathogens, lack of nutrients, cytokines, irradiation, mechanical stress, or ER stress. The PKR pathway leads to a stress response through activation of other stress pathways such as JNK, p38, NFkB, PP2A and phosphorylation of eIF2α. ER stress caused by excess of unfolded proteins leads to inflammatory responses. PKR contributes to this response by interacting with several inflammatory kinases such as IKK, JNK, ElF2α, insulin receptors and others. This metabolically activated inflammatory complex is called metabolic inflammasome or metaflammasome. Via the JNK signaling pathway, PKR also plays a role in insulin resistance, diabetes, and obesity by phosphorylating IRS1. Inhibiting PKR in mice led to lower inflammation in adipose tissues, increased sensitivity to insulin, and amelioration of diabetic symptoms. PKR also participates in the mitochondrial unfolded protein response (UPRmt). Here, PKR is induced via the transcription factor AP-1 and activated independently of PACT. In this context, PKR has been shown to be relevant to intestinal inflammation.

Viral defense

Viruses have developed many mechanisms to counteract the PKR mechanism. It may be done by Decoy dsRNA, degradation, hiding of viral dsRNA, dimerization block, dephosphorylation of substrate or by a pseudosubstrate. Some mechanisms are still unknown, for instance, in Lymphocytic choriomeningitis virus infection the virus is not recognized by PKR, and the current anti-dsRNA antibodies have limitation in detecting dsRNA species of negative stranded RNA viruses, which necessitates the use of a different approach to understand this viral defense mechanism.

For instance, Epstein–Barr virus (EBV) uses the gene EBER1 to produce decoy dsRNA. This leads to cancers such as Burkitt's lymphoma, Hodgkin's disease, nasopharyngeal carcinoma and various leukemias.

Memory and learning

PKR knockout mice or inhibition of PKR in mice enhances memory and learning.

Neuronal degeneration disease

First report in 2002 has been shown that immunohistochemical marker for phosphorylated PKR and eIF2α was displayed positively in degenerating neurons in the hippocampus and the frontal cortex of patients with Alzheimer's disease (AD), suggesting the link between PKR and AD. Additionally, many of these neurons were also immunostained with an antibody for phosphorylated Tau protein. Activated PKR was specifically found in the cytoplasm and nucleus, as well as co-localized with neuronal apoptotic markers. Further studies have assessed the levels of PKR in blood and cerebrospinal fluid (CSF) of AD patients and controls. The result of an analysis of the concentrations of total and phosphorylated PKR (pPKR) in peripheral blood mononuclear cells (PBMCs) in 23 AD patients and 19 control individuals showed statistically significant increased levels of the ratio of phosphorylated PKR/PKR in AD patients compared with controls. Assessments of CSF biomarkers, such as Aβ1-42, Aβ1-40, Tau, and phosphorylated Tau at threonine 181, have been a validated use in clinical research and in routine practice to determine whether patients have CSF abnormalities and AD brain lesions. A study found that "total PKR and pPKR concentrations were elevated in AD and amnestic mild cognitive impairment subjects with a pPKR value (optical density units) discriminating AD patients from control subjects with a sensitivity of 91.1% and a specificity of 94.3%. Among AD patients, total PKR and pPKR levels correlate with CSF p181tau levels. Some AD patients with normal CSF Aß, T-tau, or p181tau levels had abnormal total PKR and pPKR levels". It was concluded that the PKR-eIF2α pro-apoptotic pathway could be involved in neuronal degeneration that leads to various neuropathological lesions as a function of neuronal susceptibility.

PKR and beta amyloid

Activation of PKR can cause accumulation of amyloid β-peptide (Aβ) via de-repression of BACE1 (β-site APP Cleaving Enzyme) expression in Alzheimer Disease patients. Normally, the 5′ untranslated region (5′ UTR) in the BACE1 promoter would fundamentally inhibit the expression of BACE1 gene. However, BACE1 expression can be activated by phosphorylation of eIF2a, which reverses the inhibitory effect exerted by BACE1 5′ UTR. Phosphorylation of eIF2a is triggered by activation of PKR. Viral infection such as herpes simplex virus (HSV) or oxidative stress can both increase BACE1 expression through activation of PKR-eIF2a pathway.

In addition, the increased activity of BACE1 could also lead to β-cleaved carboxy-terminal fragment of β-Amyloid precursor protein (APP-βCTF) induced dysfunction of endosomes in AD. Endosomes are highly active β-Amyloid precursor protein (APP) processing sites, and endosome abnormalities are associated with upregulated expression of early endosomal regulator, Rab5. These are the earliest known disease-specific neuronal response in AD. Increased activity of BACE1 leads to synthesis of the APP-βCTF. An elevated level of βCTF then causes Rab5 overactivation. βCTF recruits APPL1 to rab5 endosomes, where it stabilizes active GTP-Rab5, leading to pathologically accelerated endocytosis, endosome swelling and selectively impaired axonal transport of Rab5 endosomes.

PKR and Tau phosphorylation

It is reported earlier that phosphorylated PKR could co-localize with phosphorylated Tau protein in affected neurons. A protein phosphatase-2A inhibitor (PP2A inhibitor) – okadaic acid (OA) – is known to increase tau phosphorylation, Aβ deposition and neuronal death. It is studied that OA also induces PKR phosphorylation and thus, eIF2a phosphorylation. eIF2a phosphorylation then induces activation of transcription factor 4 (ATF4), which induces apoptosis and nuclear translocation, contributing to neuronal death.

Glycogen synthase kinase 3β (GSK-3β) is responsible for tau phosphorylation and controls several cellular functions including apoptosis. Another study demonstrated that tunicamycin or Aβ treatment can induce PKR activation in human neuroblastoma cells and can trigger GSK3β activation, as well as tau phosphorylation. They found that in AD brains, both activated PKR and GSK3β co-localize with phosphorylated tau in neurons. In SH-SY5Y cell cultures, tunicamycin and Aβ(1-42) activate PKR, which then can modulate GSK-3β activation and induce tau phosphorylation, apoptosis. All these processes are attenuated by PKR inhibitors or PKR siRNA. PKR could represent a crucial signaling point relaying stress signals to neuronal pathways by interacting with transcription factor or indirectly controlling GSK3β activation, leading to cellular degeneration in AD.

Fetal alcohol syndrome

PKR also mediates ethanol-induced protein synthesis inhibition and apoptosis which is linked to fetal alcohol syndrome.

Interactions

Protein kinase R has been shown to interact with:

• ASK1,
• DNAJC3,
• ILF3,
• METAP2,
• P53,
• PPP1CA,
• PRKRA,
• STAT1, and
• TARBP2.

References

References

1. "Entrez Gene: EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2".
2. (June 1992). "Identification of double-stranded RNA-binding domains in the interferon-induced double-stranded RNA-activated p68 kinase". Proceedings of the National Academy of Sciences of the United States of America.
3. (January 2021). "Emerging role of protein kinases in diabetes mellitus: From mechanism to therapy". Academic Press.
4. (May 2019). "The search for a PKR code-differential regulation of protein kinase R activity by diverse RNA and protein regulators". RNA.
5. (2019-01-01). "The Role of Nucleic Acid Sensing in Controlling Microbial and Autoimmune Disorders". Academic Press.
6. (March 2020). "Protein kinase R and its cellular regulators in cancer: An active player or a surveillant?". Wiley Interdisciplinary Reviews. RNA.
7. (July 2019). "Structural Basis of Protein Kinase R Autophosphorylation". Biochemistry.
8. (2019). "PKR: A Kinase to Remember". Frontiers in Molecular Neuroscience.
9. (2021). "Protein Kinase R in Bacterial Infections: Friend or Foe?". Frontiers in Immunology.
10. (September 2015). "PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 mice". Blood.
11. (September 2007). "The double-strand RNA-dependent protein kinase PKR plays a significant role in a sustained ER stress-induced apoptosis". FEBS Letters.
12. (December 2006). "Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action". Microbiology and Molecular Biology Reviews.
13. (March 2010). "Endoplasmic reticulum stress and the inflammatory basis of metabolic disease". Cell.
14. (2016-01-01). "Endogenous Retroelements and the Host Innate Immune Sensors". Academic Press.
15. (September 2012). "Induction of dsRNA-activated protein kinase links mitochondrial unfolded protein response to the pathogenesis of intestinal inflammation". Gut.
16. (2024-03-19). "Activation of protein kinase receptor (PKR) plays a pro-viral role in mammarenavirus-infected cells". Journal of Virology.
17. (2006-05-15). "Double-Stranded RNA Is Produced by Positive-Strand RNA Viruses and DNA Viruses but Not in Detectable Amounts by Negative-Strand RNA Viruses". Journal of Virology.
18. (2024-03-19). "Activation of protein kinase receptor (PKR) plays a pro-viral role in mammarenavirus-infected cells". Journal of Virology.
19. (December 2002). "Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer's disease". NeuroReport.
20. (2006). "Activated double-stranded RNA-dependent protein kinase and neuronal death in models of Alzheimer's disease". Neuroscience.
21. (2006). "Activated mTOR and PKR kinases in lymphocytes correlate with memory and cognitive decline in Alzheimer's disease". Dementia and Geriatric Cognitive Disorders.
22. (May 2012). "Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease". Biological Psychiatry.
23. (2011-06-28). "Activation of PKR causes amyloid ß-peptide accumulation via de-repression of BACE1 expression". PLOS ONE.
24. (June 2012). "Oxidative stress increases BACE1 protein levels through activation of the PKR-eIF2α pathway". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.
25. (May 2016). "Evidence that the rab5 effector APPL1 mediates APP-βCTF-induced dysfunction of endosomes in Down syndrome and Alzheimer's disease". Molecular Psychiatry.
26. (October 2003). "Activation of the cell stress kinase PKR in Alzheimer's disease and human amyloid precursor protein transgenic mice". Neurobiology of Disease.
27. (September 2010). "Activation of eukaryotic initiation factor-2 α-kinases in okadaic acid-treated neurons". Neuroscience.
28. (March 2011). "Modulation of tau phosphorylation by the kinase PKR: implications in Alzheimer's disease". Brain Pathology.
29. (June 2006). "Interaction between RAX and PKR modulates the effect of ethanol on protein synthesis and survival of neurons". The Journal of Biological Chemistry.
30. (December 2002). "Double-stranded RNA-activated protein kinase interacts with apoptosis signal-regulating kinase 1. Implications for apoptosis signaling pathways". European Journal of Biochemistry.
31. (January 1996). "The P58 cellular inhibitor complexes with the interferon-induced, double-stranded RNA-dependent protein kinase, PKR, to regulate its autophosphorylation and activity". The Journal of Biological Chemistry.
32. (August 2001). "Characterization of two evolutionarily conserved, alternatively spliced nuclear phosphoproteins, NFAR-1 and -2, that function in mRNA processing and interact with the double-stranded RNA-dependent protein kinase, PKR". The Journal of Biological Chemistry.
33. (May 1999). "Nuclear factor-90 of activated T-cells: A double-stranded RNA-binding protein and substrate for the double-stranded RNA-dependent protein kinase, PKR". Biochemistry.
34. (August 2001). "Nuclear factor 90 is a substrate and regulator of the eukaryotic initiation factor 2 kinase double-stranded RNA-activated protein kinase". The Journal of Biological Chemistry.
35. (July 1999). "DRBP76, a double-stranded RNA-binding nuclear protein, is phosphorylated by the interferon-induced protein kinase, PKR". The Journal of Biological Chemistry.
36. (December 2000). "In vivo regulation of the dsRNA-dependent protein kinase PKR by the cellular glycoprotein p67". Biochemistry.
37. (April 1999). "The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro". Oncogene.
38. (September 2002). "The direct binding of the catalytic subunit of protein phosphatase 1 to the PKR protein kinase is necessary but not sufficient for inactivation and disruption of enzyme dimer formation". The Journal of Biological Chemistry.
39. (August 2002). "The C-terminal, third conserved motif of the protein activator PACT plays an essential role in the activation of double-stranded-RNA-dependent protein kinase (PKR)". The Biochemical Journal.
40. (August 1998). "PACT, a protein activator of the interferon-induced protein kinase, PKR". The EMBO Journal.
41. (March 1997). "Physical association between STAT1 and the interferon-inducible protein kinase PKR and implications for interferon and double-stranded RNA signaling pathways". The EMBO Journal.
42. (April 2001). "Enhanced antiviral and antiproliferative properties of a STAT1 mutant unable to interact with the protein kinase PKR". The Journal of Biological Chemistry.
43. (October 1995). "Double-stranded-RNA-dependent protein kinase and TAR RNA-binding protein form homo- and heterodimers in vivo". Proceedings of the National Academy of Sciences of the United States of America.
44. (September 2001). "Two dimerization domains in the trans-activation response RNA-binding protein (TRBP) individually reverse the protein kinase R inhibition of HIV-1 long terminal repeat expression". The Journal of Biological Chemistry.